Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTS6PQYL)

DOT Name Dual specificity protein phosphatase 15 (DUSP15)
Synonyms EC 3.1.3.16; EC 3.1.3.48; VH1-related member Y; Vaccinia virus VH1-related dual-specific protein phosphatase Y
Gene Name DUSP15
Related Disease
Autism ( )
Multiple sclerosis ( )
UniProt ID
DUS15_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1YZ4
EC Number
3.1.3.16; 3.1.3.48
Pfam ID
PF00782
Sequence
MTEGVLPGLYLGNFIDAKDLDQLGRNKITHIISIHESPQPLLQDITYLRIPVADTPEVPI
KKHFKECINFIHCCRLNGGNCLVHCFAGISRSTTIVTAYVMTVTGLGWRDVLEAIKATRP
IANPNPGFRQQLEEFGWASSQKGARHRTSKTSGAQCPPMTSATCLLAARVALLSAALVRE
ATGRTAQRCRLSPRAAAERLLGPPPHVAAGWSPDPKYQICLCFGEEDPGPTQHPKEQLIM
ADVQVQLRPGSSSCTLSASTERPDGSSTPGNPDGITHLQCSCLHPKRAASSSCTR
Function
May dephosphorylate MAPK13, ATF2, ERBB3, PDGFRB and SNX6 ; [Isoform 3]: May play a role in the regulation of oligodendrocyte differentiation. May play a role in the regulation of myelin formation. Involved in the regulation of Erk1/2 phosphorylation in Schwann cells; the signaling may be linked to the regulation of myelination.
Tissue Specificity Highly expressed in testis . Expressed in brain; up-regulated in patients with multiple sclerosis gray matter lesions .

Molecular Interaction Atlas (MIA) of This DOT

2 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Autism DISV4V1Z Strong Genetic Variation [1]
Multiple sclerosis DISB2WZI Strong Altered Expression [2]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
4 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Bortezomib DMNO38U Approved Bortezomib decreases the expression of Dual specificity protein phosphatase 15 (DUSP15). [3]
Urethane DM7NSI0 Phase 4 Urethane increases the expression of Dual specificity protein phosphatase 15 (DUSP15). [4]
Leflunomide DMR8ONJ Phase 1 Trial Leflunomide increases the expression of Dual specificity protein phosphatase 15 (DUSP15). [5]
Resorcinol DMM37C0 Investigative Resorcinol decreases the expression of Dual specificity protein phosphatase 15 (DUSP15). [6]
------------------------------------------------------------------------------------

References

1 Association of oligodendrocytes differentiation regulator gene DUSP15 with autism.World J Biol Psychiatry. 2017 Mar;18(2):143-150. doi: 10.1080/15622975.2016.1178395. Epub 2016 May 25.
2 Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach.PLoS One. 2012;7(7):e40457. doi: 10.1371/journal.pone.0040457. Epub 2012 Jul 11.
3 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
4 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
5 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
6 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.